We understand the ways in which pulmonary hypertension and pulmonary arterial hypertension can impair daily life, and are committed to helping to improve understanding and speedy diagnoses of these diseases within the medical profession. We are here to help you lead a normal life and get optimal treatment quickly and easily.
Understanding Pulmonary Hypertension
Of the five groups of PH, our research is focused on improving patient outcomes in Pulmonary Arterial Hypertension (PAH), as well as other groups.
Our goal is to give people with PH a normal life
At Janssen, we are spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.
We want to use our full range of resources to tackle PH. From investment in research and development to innovation in medical devices and diagnostics, our commitment to building an innovative drug development pipeline is real. We're focused not only on how we treat PH but on a broader spectrum of goals for the PH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.
Our work is defined by our patient pledge: ‘With You Until PH Isn’t’
We want to:
Maximise the clinical benefits of our current medicines
Drive early identification and diagnosis of PH
Build an innovative drug development future that focuses on new ways to tackle PAH
Invest in diagnostics and biomarkers to speed up referrals to specialist centres
PAH Patient Charter
A PAH charter, co-created with the patient community and launched in 2019, outlines what we think patients with PAH should expect from their healthcare.
Pulmonary hypertension facts
The majority of patients are in advanced stage (functional class III or IV) at time of diagnosis.
We’re focused on Pulmonary Arterial Hypertension (PAH)
Within the field of Pulmonary Hypertension (PH), we are concentrating on Pulmonary Arterial Hypertension (PAH).
PAH (Group I, Pulmonary Hypertension) is a rare, progressive and relentless disease, where the pressure in the blood vessels of the lungs is elevated, resulting in stress on the heart.
Despite recent advances, PAH remains a severely debilitating condition that leads to heart disease and early death.,  Early diagnosis and treatment are critical to helping improve life expectancy, but PAH is difficult to diagnose and there is currently no cure.
Our research is focused on improving patient outcomes in PAH. We’re working to transform PAH into a long-term, manageable condition and to one day find a cure for it. Janssen’s aim is to increase the mainstream awareness around PAH so that no patient goes undiagnosed and there’s no delay in diagnosis.
Our pioneering medicines have contributed to improved patient outcomes for PAH communities
Our deep understanding of the complex pathways and molecular mechanisms involved in PAH has resulted in the development of tailored medicines that have significantly improved patient outcomes.
We have a number of clinical trials ongoing which form a core part of our clinical development plan. We are searching for novel compounds that can focus on disease-modifying pathways and we’re investing in non- and less-invasive diagnostics and blood- and breath-based biomarkers to aid faster referral to specialist centres.
“At Janssen, we are committed to transforming pulmonary arterial hypertension into a long-term, manageable condition so that patients can live a normal life. Our integration has created unique perspectives, opportunities and capabilities that we hope will provide new possibilities for the PH community.”
EMEA Medical Director, Pulmonary Hypertension
Janssen is the Global Leader in Pulmonary Hypertension
In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. We have made PH a ‘therapeutic area of focus’ and are committed to maintaining and building on the leadership position that Actelion has built in this important disease area.
We respect and value Actelion’s legacy in Pulmonary Arterial Hypertension (PAH), a rare form of PH, and we are proud that Actelion is now part of Janssen’s portfolio.
Janssen is the natural partner for Actelion, sharing the same passion for science and the same dedicated commitment to improving the welfare of patients.
We bring to the field of PH a remarkable track record in scientific discovery and a deep patient-centric focus, underpinned by an open, transparent business culture. We have 16 medicines on the World Health Organization (WHO) Essential Medicines List.
As the global industry leader in PAH, Janssen is the partner of choice for collaborations in the disease area. We actively explore business partnership opportunities in pharmaceuticals, diagnostics, therapeutic devices and digital health to support our goal to transform PAH into a long-term, manageable disease.
We are pleased to collaborate with patient organisations, too, in supporting their mission to empower patients with PH to optimally manage their disease and lead as normal a life as possible. Janssen has unique access to new diagnostic technologies and novel medical devices that aim to extend the benefit of its PH portfolio.Our Collaborations
Putting Patients First
“I would describe PAH as like being in a car which won't go over 10KPH”
Patient with PAH
For support, information and inspiration on living with PAH, head to our PHUMAN site. There you’ll find patient stories, tips and information, and support – whether you’re a patient, a carer, or a healthcare worker.Phuman
 Galiè N, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2015; 46:903-975.
 J&J gcs-web, Janssen Pulmonary Hypertension Website 2019. Available: https://johnsonandjohnson.gcs-web.com/static-files/c6f5737b-4a1c-4fba-b90d-7fcbb844bf79. Accessed: November 2020
 Benza RL, et al. An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry. Chest 2012; 142:448 56.
 Hoeper MM, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50:1700740.
 Vachiéry JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012; 21:313-20.
 Prins KW, et al. WHO Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin 2016; 34(3):363 74.
 Humbert M, et al. Pulmonary Arterial Hypertension in France. Am J Respir Crit Care Med 2006; 173:1023 30.
 Hoeper MG, Gibbs SR. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev 2014; 23:450-7.
 Brown LM, et al. Delay in recognition of pulmonary arterial hypertension. Factors identified from the REVEAL registry. Chest 2011; 140(1):19-26.
 J&J. Johnson & Johnson Announces Completion of Acquisition of Actelion. Available at: https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-completion-of-acquisition-of-actelion. Accessed: November 2020.
 WHO. Model List of Essential Medicines. Available at: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-... Accessed: October 2020.